Post Reply
421-440 of 828
Something is brewing.......
antifragile ( Date: 17-Jun-2021 16:26) Posted:
|
$1.....
antifragile ( Date: 17-Jun-2021 16:18) Posted:
|
Something is brewing.....
Privatisation???
Privatisation???
antifragile ( Date: 15-Apr-2021 00:08) Posted:
|
Potential target to be acquired....!
ValueSeer ( Date: 14-Apr-2021 20:13) Posted:
|
This came up in a search. Net cash is 71% of current market cap. Profit margin % is trending up
$0.8....!
Goh Jin Hian steps down as Cordlife chairman but staying on as ID
GOH Jin Hian has left his post as chairman of Cordlife Group with immediate effect, although he continues to serve as an independent director. He also remains the non-executive chairman of New Silkroutes Group.
The announcement comes after Inter-Pacific Petroleum' s (IPP) judicial managers (JMs) sued him in relation to an alleged breach of director' s duties. Dr Goh, the medically trained son of former Singapore prime minister Goh Chok Tong, is ceasing the role " to devote more time to his personal affairs" , said Cordlife in a filing late Monday night.
In the meantime, Ho Choon Hou, vice-chairman and independent director, was named the acting chairman of the mainboard-listed cord-blood banking firm.
Deloitte & Touche, the JMs of insolvent marine fuel and cargo trader IPP, filed the suit against Dr Goh in the Singapore High Court on Friday night.
He was IPP' s executive director from 2011 to late 2014, and then non-executive director until August 2019.
The lawsuit is funded by IPP' s two major bank creditors, Societe Generale (SocGen) and Maybank, which are seeking to recover losses they claim were a result of his alleged negligence, according to court documents seen by The Business Times (BT).
Cordlife' s nominating committee (NC) and board said it would be appropriate to allow the legal proceedings to run its due course.
The cessation of Dr Goh' s role as chairman will allow him to give sufficient time and attention to the company' s affairs as an independent director, Cordlife added.
At the same time, the NC and board believe he " has the character and integrity suitable to continue as independent director" . Given his qualifications, expertise and experience, it is in the best interests of the company for him to remain in that role, they noted.
Meanwhile, mainboard-listed New Silkroutes Group on Tuesday said it believes Dr Goh is suitable to continue as a director of the healthcare and energy firm despite the litigation. This is because it is a civil suit against him, and the allegations are without merit, based on his lawyers' legal advice, New Silkroutes said.
TSMP advised Dr Goh that the JMs' allegations are without merit both on the facts and on the law.
New Silkroutes' board added that he " has every confidence that he will be wholly vindicated when he defends himself in court" .
Dr Goh was also chief executive of New Silkroutes, but vacated the role last Thursday.
Separately, he is assisting with the Commercial Affairs Department' s probe into a possible offence under the Securities and Futures Act in relation to New Silkroutes.
Cordlife says chairman Goh Jin Hian can fulfil duty while assisting with CAD probe
CORDLIFE Group' s board on Friday said it is supportive of Goh Jin Hian' s continued service as chairman and independent director.
This is even as the 51-year-old - who is the son of former Singapore prime minister Goh Chok Tong - is assisting with the Commercial Affairs Department' s (CAD) investigations in relation to healthcare and energy firm New Silkroutes Group.
The Singapore police' s CAD is looking into a possible offence under the Securities and Futures Act, and New Silkroutes on Wednesday said it understood that the alleged offence is false trading and market rigging, in view of past share buybacks and share purchases.
Dr Goh, who was chief executive officer (CEO) of New Silkroutes until he vacated the role on Thursday, is one of the individuals assisting CAD with the investigations. He remains the chairman of New Silkroutes.
Cordlife' s board - with Dr Goh abstaining - on Friday said it is of the view that his assistance with the probe " does not compromise his ability to fulfil his duty as the chairman and independent director of the company" , based on the information currently available to the board.
In its assessment of the suitability of Dr Goh' s service on the board, Cordlife will monitor the progress of the CAD investigations, and will make further announcements as and when there are any material developments.
The board will request that he updates it on the progress of the probe, in order for the company to comply with disclosure obligations under listing rules.
As far as the board is aware, the investigations are not related to Cordlife or its subsidiaries. Accordingly, the business and operations are not expected to be affected.
Besides Dr Goh, New Silkroutes finance director William Teo and its former chief corporate officer Kelvyn Oo are also assisting with the investigations. Mr Oo, who left New Silkroutes in August, is an independent director of Catalist-listed oil and gas-related company Teho International.
New Silkroutes on Thursday appointed a new CEO, specialist orthodontist VicPearly Wong.
Separately, Singapore' s High Court has approved two major bank creditors' bid to fund Inter-Pacific Petroleum' s (IPP) lawsuit against Dr Goh, IPP' s former director, The Business Times reported. Societe Generale and Maybank are seeking to recover at least US$156 million in losses they claim were a result of Dr Goh' s alleged negligence, according to court documents.
Shares of mainboard-listed Cordlife, which provides private cord-blood banking services, last traded on Wednesday at S$0.36.
Big business
beng1102 ( Date: 01-Jun-2020 12:04) Posted:
|
Cordlife sees growing adoption of cord-blood banking
The penetration rate in most of Asia is low, but is likely to rise with the rise of the middle class
GROWING up with asthma, healthcare industry veteran Tan Poh Lan, 58, found hospitals and emergency waiting rooms familiar territory.
The group chief executive officer of Singapore Exchange-listed cord blood banking services company Cordlife Group said: " I was horribly asthmatic as a kid, and spent time in hospitals whenever I suffered an attack.
" And because I loved the sciences, particularly biology, I wanted to build a career in healthcare."
She began her career as an occupational therapist with Singapore General Hospital, where she learnt to deal with challenges head-on and look for solutions. " For example, how do you help a handicapped client cope with daily tasks and routines? There' s a way we just have to find it."
This attitude has followed her through a three decade-long career in the private and public healthcare sectors, both in Singapore and the region.
She joined Mount Elizabeth Hospital in 1991 as a marketing executive and rose through the ranks to become its chief executive officer (CEO) in 2007. Between that year and 2015, she held CEO roles in other local and regional hospitals, including Parkway East Hospital (formerly East Shore Hospital) and Gleneagles Hospital in Singapore, and Vinmec International Hospital in Hanoi, Vietnam, and Fortis Healthcare Singapore.
Ms Tan was appointed group chief operating officer of Cordlife in 2016, and promoted to group CEO three years later.
Incorporated in 2001 and listed on SGX' s mainboard since 2012, Cordlife is a pioneer in private cord-blood banking in Asia. It owns the largest network of cord blood banks in the region, with full stem cell banking facilities in the six key markets of Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. Through marketing agents, Cordlife extended its presence to Myanmar and Vietnam in 2017, and Bangladesh in 2019.
Market leadership
Cordlife operates the largest private cord-blood banks in Singapore, the Philippines and Indonesia, and is among the top three market leaders in India and Malaysia. The group became the market leader in Hong Kong via the acquisition of Healthbaby Biotech in 2018. Through a Malaysian subsidiary, it also holds an indirect stake in Thailand' s largest private cord-blood bank, Thai Stemlife.
Beyond cord blood and cord-lining banking, Cordlife offers a comprehensive suite of diagnostic services for the family, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
All the group' s facilities are accredited by the American Association of Blood Banks (AABB), the organisation behind the world' s gold standard for cord-blood banking. In addition, Cordlife Singapore and Healthbaby Hong Kong are also two of four cord blood banks in Asia, and 10 in the world, to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (FACT), another world-class accreditation body for cord-blood banks.
In the area of clinical diagnostics, Cordlife India, Cordlife Hong Kong and Healthbaby are also accredited by the College of American Pathologists.
When Ms Tan joined Cordlife, she made it a priority to streamline the group' s operations. " We brought some previously outsourced functions back into the group, and facilitated collaboration among the different markets, all of which have led to significant cost savings," she said.
For the six months ended June 30, net profit jumped 50.2 per cent year on year to S$2.63 million, even as revenue declined 12.7 per cent to S$26.2 million. Net profit margin edged up 4.2 percentage points to 10 per cent.
But cost-cutting only goes so far, she said. " Prudent expense management is not enough - we need to boost revenues as well."
The group has thus been ramping up new revenue channels, including its diagnostics and digital healthcare business segments, to complement its core operations.
" Stem cell therapeutics are subject to regulatory oversight in each operating country. We welcome government efforts to set ethical guidelines that will enable our industry to progress cautiously and responsibly, as well as to grow in a healthy manner," Ms Tan said.
Cordlife has observed an encouraging trend of better alignment of regulations and guidance for stem-cell therapeutics globally. As interest in stem-cell therapy grows, its banking business will be a primary beneficiary, especially in the area of cellular therapies and regenerative medicine.
" Our various country heads are proactively working to develop an ecosystem, with doctors and hospitals in their respective countries to encourage utilisation of stem cells."
The results from Cordlife' s diagnostics services segment have also been encouraging. Revenue contribution from this segment grew 68 per cent to S$1.6 million in FY2019 from S$0.9 million the year before. " Diagnostics is a growth engine for all our markets and is expected to drive our business forward."
Middle-class market
Generating and boosting awareness of the potential of cord blood, cord tissue and cord-lining banking is another focus.
Cord blood banking involves the collection at birth, processing, testing, cryopreservation and storage of stem cells from umbilical cord blood. Cord tissue and cord-lining banking refer to the collection, processing, testing, cryopreservation and storage of the umbilical cord tissue or lining. The process for cord-lining banking uses patented technology from Singapore-based stem cell technology firm CellResearch Corporation via an exclusive licence.
The current penetration rates in Malaysia, India, the Philippines, Indonesia, Vietnam, Myanmar and Bangladesh remain relatively low - in the single digits, versus Singapore' s double-digit rates.
" But we believe there is huge potential for growth in these countries as healthcare spending by the progressive middle and affluent classes is on the rise," she said. " Once you' re able to capture the attention of mothers-to-be, it' s easier to get their buy-in it' s usually the women who make the family' s healthcare decisions."
Cordlife is also developing its mobile application, Moms Up, which provides health information and resources to help Asian women who plan to conceive or are expecting, as well as mothers with young children. It aims to roll out the app by year-end.
" Leveraging on this digital platform, we intend to expand our reach to potential clients and increase touch points with existing customers," she said.
Apart from driving organic growth, Cordlife is also seeking acquisitions to strengthen its market position, and expand its footprint beyond its current 10 markets in Asia.
" We will review any horizontal integration opportunities to add to the group' s revenue and earnings growth," she said. " These targets will be synergistic to our existing businesses and provide a competitive edge over other market players."
China is one market it has been exploring, with the abolishment of the country' s one-child policy brewing opportunities in cord-blood banking there.
Digitalisation drive
In the meantime, she is managing the fallout from the coronavirus pandemic. " Covid-19 has affected demand for the group' s banking services and tightened consumer spending, resulting in lower client acquisitions," she said.
And with some of its key markets facing recurring waves of the outbreak, uncertainties are expected up ahead.
With social-distancing measures and border controls curbing Cordlife' s physical promotional activities or delivery of services, the group has mounted digital initiatives, including online consultations, webinars and e-enrolment to engage potential clients.
Other roadblocks include declining or stagnating birth rates in Cordlife' s target market segments. It is a known trend that middle- to upper-class urban professionals have fewer babies, but " the good news is that each child becomes very precious, and as these parents get more affluent, they have higher disposable incomes to invest in their children. With more services, including diagnostics, we' re able to offer bundling of services and products" .
Ms Tan also worries about developing a deep talent bench in Cordlife: " Organisational success is often linked to an inspiring vision, a clear mission and strong values. But do I have enough of the right people - not just for Singapore, but also for our other markets?"
And in an increasingly interconnected and digital environment, cyber security is another issue that looms large. " The growing risks and threats to IT security cannot be ignored. Covid has fast-forwarded our move online, and we need to ensure the safety, security and confidentiality of all our clients' data."
0.60 coming. Jeremy Yee in Biolidics , still involved in Cordlife?
Back to life.... still not too late to hop in....
Good news. Buy and hold for long like to surge to very high price.
Studies suggest that the use of mesenchymal stem cells collected from umbilical cord blood and tissue are a safe and effective way to alleviate symptoms of coronavirus and promote fast recovery
https://www.openaccessgovernment.org/umbilical-cord-stem-cells-have-the-potential-to-treat-covid-19/86763/
beng1102 ( Date: 01-Jun-2020 11:51) Posted:
|
China major shareholders will make it big.
| SmallSmall ( Date: 01-Jun-2020 11:36) Posted: |
Time to buy. https://www.youtube.com/watch?v=3Ag534o5fTk
Cord blood is being used in a world first clinical trial for severe COVID-19 patients. It is anticipated that the patient will improve within 24 of cord blood transfusion.
Cord blood is being used in a world first clinical trial for severe COVID-19 patients. It is anticipated that the patient will improve within 24 of cord blood transfusion.
drifter198 ( Date: 13-May-2020 11:19) Posted:
|
Cordlife&rsquo s 1Q2020 net profit grows 69.9% yoy to S$1.5 million with higher net profit margin of 10.3%
&bull Gross profit margin and net profit margin were higher at 63.2% and 10.3% respectively.
&bull Net cash position increased to S$58.0 million, mainly driven by net operating cash flows of S$3.5 million.
&bull The Group continues to look for business opportunities proactively.
Link: https://links.sgx.com/1.0.0/corporate-announcements/H35S8C9P189EMMO2/be63e62b97336c408549fcbc703dd6f45578d178a33779930fa151bb8836f6af
&bull Gross profit margin and net profit margin were higher at 63.2% and 10.3% respectively.
&bull Net cash position increased to S$58.0 million, mainly driven by net operating cash flows of S$3.5 million.
&bull The Group continues to look for business opportunities proactively.
Link: https://links.sgx.com/1.0.0/corporate-announcements/H35S8C9P189EMMO2/be63e62b97336c408549fcbc703dd6f45578d178a33779930fa151bb8836f6af
sth. brewing?
win liao lo.....still no new announce....???
speculation??
speculation??
Maybe gg to update on non-binding proposal with Global Cord Blood Coorporation...
Lets see whether will chiong further...
Lets see whether will chiong further...
Berani ( Date: 10-Jul-2019 13:25) Posted:
|